<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901897</url>
  </required_header>
  <id_info>
    <org_study_id>893</org_study_id>
    <nct_id>NCT04901897</nct_id>
  </id_info>
  <brief_title>Product Performance of a New Silicone Hydrogel Contact Lens</brief_title>
  <official_title>A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the product performance of kalifilcon A, compared&#xD;
      to the Johnson &amp; Johnson Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable&#xD;
      contact lens and Alcon DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses when&#xD;
      worn by current soft contact lens wearers on a daily disposable wear basis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Actual">October 9, 2019</completion_date>
  <primary_completion_date type="Actual">October 9, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in logMAR Contact Lens Visual Acuity</measure>
    <time_frame>Baseline, 2 Week Follow up</time_frame>
    <description>logMAR is the logarithm of the minim angle of resolution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in the Test Lens Group Agreeing With the Statement &quot;Are Comfortable Throughout the Day&quot;</measure>
    <time_frame>2 Week Follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in the Test Lens Group Agreeing With the Statement &quot;Provide Clear Vision Throughout the Day&quot;</measure>
    <time_frame>2 Week Follow up</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">805</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>kalifilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>kalifilcon A daily disposable contact lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>delefilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>kalifilcon A</intervention_name>
    <description>kalifilcon A daily disposable contact lens</description>
    <arm_group_label>kalifilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>delefilcon A</intervention_name>
    <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
    <arm_group_label>delefilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A</intervention_name>
    <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
    <arm_group_label>senofilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 40 years old on the date the ICF is signed and have capacity to provide&#xD;
             voluntary informed consent.&#xD;
&#xD;
          -  myopic and require lens correction from -0.50 to -6.00 Diopter (D) with 0.25 D steps,&#xD;
             in each eye.&#xD;
&#xD;
          -  correctable through spherocylindrical refraction and with soft spherical contact&#xD;
             lenses to 32 letters (0.3 logarithm of the minimum angle of resolution [logMAR]) or&#xD;
             better (2 meters distance, high-contrast chart) in each eye.&#xD;
&#xD;
          -  free of any anterior segment disorders.&#xD;
&#xD;
          -  adapted soft contact lens wearers and willing to wear their study lenses for at least&#xD;
             8 hours per day on a daily disposable wear basis for approximately 2 weeks.&#xD;
&#xD;
          -  access to internet connection and personal email to send/receive emails.&#xD;
&#xD;
          -  habitually wear either Alcon's Air Optix Aqua, Air Optix with HydraGlyde, Air Optix&#xD;
             Night &amp; Day, Bausch + Lomb's PureVision 2, Bausch + Lomb ULTRA, CooperVision's&#xD;
             Biofinity, Johnson &amp; Johnson Acuvue Oasys® with HydraClear™, or Acuvue Vita soft&#xD;
             contact lenses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  participating in any drug or device clinical investigation within 2 weeks prior to&#xD;
             entry into this study (Screening/Dispensing Visit) and/or during the period of study&#xD;
             participation.&#xD;
&#xD;
          -  have worn gas permeable (GP) contact lenses within the last 30 days or who have worn&#xD;
             polymethylmethacrylate (PMMA) lenses within the last three months.&#xD;
&#xD;
          -  have any systemic or ocular disease currently affecting ocular health in the&#xD;
             Investigator's opinion may have an effect on ocular health during the course of the&#xD;
             study.&#xD;
&#xD;
          -  using any systemic, topical or topical ocular medications that will in the&#xD;
             Investigator's opinion, affect ocular physiology or lens performance.currently wear&#xD;
             daily disposable, monovision, multifocal, or toric contact lenses.&#xD;
&#xD;
          -  refractive astigmatism of greater than 0.75 D in either eye.&#xD;
&#xD;
          -  anisometropia (spherical equivalent) of greater than 2.00 D.&#xD;
&#xD;
          -  amblyopic.&#xD;
&#xD;
          -  have had any corneal surgery (e.g., refractive surgery).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Steffen</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch Site 433</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 431</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 406</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 430</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 419</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 435</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 432</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 409</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 416</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 415</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 434</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 405</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 412</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 401</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 437</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 414</name>
      <address>
        <city>Leavenworth</city>
        <state>Kansas</state>
        <zip>66048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 413</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 421</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 429</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 422</name>
      <address>
        <city>Raytown</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 407</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 418</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 424</name>
      <address>
        <city>Jamestown</city>
        <state>New York</state>
        <zip>14701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 403</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 417</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 411</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 423</name>
      <address>
        <city>Miamisburg</city>
        <state>Ohio</state>
        <zip>45342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 425</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 428</name>
      <address>
        <city>Grants Pass</city>
        <state>Oregon</state>
        <zip>97526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 420</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 427</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch 410</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 408</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>33119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 404</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 426</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <results_first_submitted>May 26, 2021</results_first_submitted>
  <results_first_submitted_qc>June 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04901897/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Kalifilcon A</title>
          <description>kalifilcon A daily disposable contact lens&#xD;
kalifilcon A: kalifilcon A daily disposable contact lens</description>
        </group>
        <group group_id="P2">
          <title>Delefilcon A</title>
          <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses&#xD;
delefilcon A: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
        </group>
        <group group_id="P3">
          <title>Senofilcon A</title>
          <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens&#xD;
senofilcon A: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="398"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="393"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kalifilcon A</title>
          <description>kalifilcon A daily disposable contact lens&#xD;
kalifilcon A: kalifilcon A daily disposable contact lens</description>
        </group>
        <group group_id="B2">
          <title>Delefilcon A</title>
          <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses&#xD;
delefilcon A: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
        </group>
        <group group_id="B3">
          <title>Senofilcon A</title>
          <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens&#xD;
senofilcon A: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="398"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="205"/>
            <count group_id="B4" value="805"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="5.72"/>
                    <measurement group_id="B2" value="30.0" spread="6.11"/>
                    <measurement group_id="B3" value="29.3" spread="5.78"/>
                    <measurement group_id="B4" value="30.3" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="527"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="574"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in logMAR Contact Lens Visual Acuity</title>
        <description>logMAR is the logarithm of the minim angle of resolution</description>
        <time_frame>Baseline, 2 Week Follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kalifilcon A</title>
            <description>kalifilcon A daily disposable contact lens&#xD;
kalifilcon A: kalifilcon A daily disposable contact lens</description>
          </group>
          <group group_id="O2">
            <title>Delefilcon A</title>
            <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses&#xD;
delefilcon A: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
          </group>
          <group group_id="O3">
            <title>Senofilcon A</title>
            <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens&#xD;
senofilcon A: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in logMAR Contact Lens Visual Acuity</title>
          <description>logMAR is the logarithm of the minim angle of resolution</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="796"/>
                <count group_id="O2" value="404"/>
                <count group_id="O3" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.0727"/>
                    <measurement group_id="O2" value="-0.069" spread="0.0733"/>
                    <measurement group_id="O3" value="-0.069" spread="0.0718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the Test Lens Group Agreeing With the Statement &quot;Are Comfortable Throughout the Day&quot;</title>
        <time_frame>2 Week Follow up</time_frame>
        <population>Participants with 2 week follow up and responded to the question.</population>
        <group_list>
          <group group_id="O1">
            <title>Kalifilcon A</title>
            <description>kalifilcon A daily disposable contact lens&#xD;
kalifilcon A: kalifilcon A daily disposable contact lens</description>
          </group>
          <group group_id="O2">
            <title>Delefilcon A</title>
            <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses&#xD;
delefilcon A: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
          </group>
          <group group_id="O3">
            <title>Senofilcon A</title>
            <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens&#xD;
senofilcon A: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Test Lens Group Agreeing With the Statement &quot;Are Comfortable Throughout the Day&quot;</title>
          <population>Participants with 2 week follow up and responded to the question.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the Test Lens Group Agreeing With the Statement &quot;Provide Clear Vision Throughout the Day&quot;</title>
        <time_frame>2 Week Follow up</time_frame>
        <population>Participants with 2 week follow up and responded to the question.</population>
        <group_list>
          <group group_id="O1">
            <title>Kalifilcon A</title>
            <description>kalifilcon A daily disposable contact lens&#xD;
kalifilcon A: kalifilcon A daily disposable contact lens</description>
          </group>
          <group group_id="O2">
            <title>Delefilcon A</title>
            <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses&#xD;
delefilcon A: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
          </group>
          <group group_id="O3">
            <title>Senofilcon A</title>
            <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens&#xD;
senofilcon A: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Test Lens Group Agreeing With the Statement &quot;Provide Clear Vision Throughout the Day&quot;</title>
          <population>Participants with 2 week follow up and responded to the question.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Adverse events occurring after signing of informed consent and through the participant's end of participation in the study were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Kalifilcon A</title>
          <description>kalifilcon A daily disposable contact lens&#xD;
kalifilcon A: kalifilcon A daily disposable contact lens</description>
        </group>
        <group group_id="E2">
          <title>Delefilcon A</title>
          <description>DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses&#xD;
delefilcon A: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses</description>
        </group>
        <group group_id="E3">
          <title>Senofilcon A</title>
          <description>Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens&#xD;
senofilcon A: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Donatello</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>5853385306</phone>
      <email>Daniel.Donatello@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

